Safety and efficacy outcomes in heavily and non-heavily pretreated patients with recurrent ovarian cancer (ROC) after single-agent trabectedin treatment: pooled analysis of phase II trials

被引：0
|
作者：
Kurzeder, C. [1 ]
Sehouli, J. [2 ]
Brugger, W. [3 ]
Zintl, P. [4 ]
De la Riba, M., I [4 ]
Kreienberg, R. [5 ]
机构：
[1] Kliniken Essen Mitte, Essen, Germany
[2] Charite, D-13353 Berlin, Germany
[3] Schwarzwald Baar Klinikum, Villingen Schwenningen, Germany
[4] PharmaMar SA, Colmenar Viejo, Spain
[5] Univ Ulm Klinikum, Ulm, Germany
来源：
ONKOLOGIE | 2011年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：222 / 223
页数：2
相关论文
共 50 条
  • [41] A randomized phase II multicenter study of single-agent paclitaxel given weekly versus every third week to patients with platinum-pretreated ovarian cancer
    Boman, K
    Andersson, H
    Rosenberg, P
    Sorbe, B
    Högberg, T
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 98 - 98
  • [42] The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial
    Jeffrey A. How
    Amir Jazaeri
    Shannon N. Westin
    Anil K. Sood
    Lois M. Ramondetta
    Mingxuan Xu
    Abdulrahman Abonofal
    Daniel D. Karp
    Vivek Subbiah
    Bettzy Stephen
    Jordi A. Rodon
    Fei Yang
    Aung Naing
    Investigational New Drugs, 2021, 39 : 829 - 835
  • [43] The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial
    How, Jeffrey A.
    Jazaeri, Amir
    Westin, Shannon N.
    Sood, Anil K.
    Ramondetta, Lois M.
    Xu, Mingxuan
    Abonofal, Abdulrahman
    Karp, Daniel D.
    Subbiah, Vivek
    Stephen, Bettzy
    Rodon, Jordi A.
    Yang, Fei
    Naing, Aung
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (03) : 829 - 835
  • [44] Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1
    Rugo, Hope S.
    Dieras, Veronique
    Cortes, Javier
    Patt, Debra
    Wildiers, Hans
    O'Shaughnessy, Joyce
    Zamora, Esther
    Yardley, Denise A.
    Carter, Gebra Cuyun
    Sheffield, Kristin M.
    Li, Li
    Andre, Valerie A. M.
    Li, Xiaohong, I
    Frenzel, Martin
    Huang, Yu-Jing
    Dickler, Maura N.
    Tolaney, Sara M.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (01) : 161 - 172
  • [45] A pooled analysis of efficacy with trabectedin as 2nd/3rd line single agent in Relapsed Ovarian Cancer (ROC) patients (pts) with a Platinum-Free Interval (PFI) of 6-12 months
    Kurzeder, C.
    Del Campo, J. M.
    Sessa, C.
    Zintl, P.
    De la Riba, M., I
    Nieto, A.
    Kreienberg, R.
    ONKOLOGIE, 2010, 33 : 190 - 191
  • [46] Utidelone for heavily pretreated metastatic castration-resistant prostate cancer after failing docetaxel treatment: An open-label, single-arm, phase II trial
    Chen, Meiting
    An, Xin
    Xue, Cong
    Li, Haifeng
    Yang, Wei
    Huang, Riqing
    Peng, Jing
    Tang, Li
    Wang, Jun
    Li, Yonghong
    Shi, Yanxia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials
    Schadendorf, Dirk
    Wolchok, Jedd D.
    Hodi, F. Stephen
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean-Jacques
    Cowey, C. Lance
    Lao, Christopher D.
    Chesney, Jason
    Robert, Caroline
    Grossmann, Kenneth
    McDermott, David
    Walker, Dana
    Bhore, Rafia
    Larkin, James
    Postow, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (34) : 3807 - +
  • [48] Salvage therapy in heavily pretreated ovarian cancer with single agent pegylated liposomal doxorubicin (PLD): Preliminary results of a multicenter phase II study of the Hellenic Co-Operative Oncology Group.
    Linardou, H
    Aravantinos, G
    Bafaloukos, D
    Skarlos, D
    Kalofonos, H
    Papadimitriou, C
    Sikiotis, C
    Sofos, G
    Karabelis, A
    Dimopoulos, MA
    ANNALS OF ONCOLOGY, 2000, 11 : 85 - 85
  • [49] Phase II study of melphalan as a single-agent infused over a 24-hour period with individual adapted dosing in patients with recurrent epithelial ovarian cancer
    Mougenot, P
    Fabbro, M
    Bressolle, F
    Pouessel, D
    Culine, S
    Pinguet, F
    ONCOLOGY REPORTS, 2006, 15 (01) : 237 - 241
  • [50] Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial
    Von Pawel, J.
    Larson, T.
    Ou, S. I.
    Limentani, S. A.
    Sandler, A. B.
    Vokes, E. E.
    Kim, S.
    Liau, K. F.
    Bycott, P. W.
    Schiller, J. H.
    EJC SUPPLEMENTS, 2007, 5 (04): : 373 - 373
12345